Avitia

Avitia.bio operates in the healthcare sector, focusing on cancer diagnostics through its minimally invasive liquid biopsy technology. The company provides next-generation sequencing (NGS) based tissue and liquid biopsy panels that deliver high accuracy, empowering healthcare providers with actionable diagnostics. Avitia's technology is particularly impactful in monitoring and treating aggressive endometrial and ovarian cancers. By integrating AI-driven molecular testing, Avitia enhances the precision and speed of cancer mutation testing, making it more accessible and cost-effective for clinical labs, especially in underserved areas. The business model revolves around providing these diagnostic solutions to healthcare providers, enabling them to improve patient monitoring and treatment response. Avitia's approach not only aims to revolutionize cancer care but also to make it more equitable and efficient, with a focus on improving early detection and survival rates in Canada and beyond.

Keywords: liquid biopsy, cancer diagnostics, AI-driven, molecular testing, endometrial cancer, ovarian cancer, NGS panels, healthcare providers, precision oncology, cost-effective.